基本信息:
- 专利标题： 항원-특이적인 T 세포 반응을 유도하는 면역 강화제로서 사용을 위한 융합 단백질
- 专利标题（英）：Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
- 专利标题（中）：用作诱导抗原特异性T细胞应答的免疫增强物的融合蛋白
- 申请号：KR1020157014330 申请日：2013-12-03
- 公开(公告)号：KR1020150097480A 公开(公告)日：2015-08-26
- 发明人： 우,치아-마오 , 창,슈-강
- 申请人： 더백스 제네틱스 백신 코포레이션, 엘티디.
- 申请人地址： *F, No. **-*, Sec. *, Ren-ai Rd., Da-an District, Taipei City, Taiwan *****, Republic of China
- 专利权人： 더백스 제네틱스 백신 코포레이션, 엘티디.
- 当前专利权人： 더백스 제네틱스 백신 코포레이션, 엘티디.
- 当前专利权人地址： *F, No. **-*, Sec. *, Ren-ai Rd., Da-an District, Taipei City, Taiwan *****, Republic of China
- 代理人： 이원희
- 优先权： US61/733,879 2012-12-05
- 国际申请： PCT/US2013/072753 2013-12-03
- 国际公布： WO2014089009 2014-06-12
- 主分类号： C07K19/00
- IPC分类号： C07K19/00 ; C07K14/005 ; C07K14/705 ; A61K39/21 ; A61K39/385 ; A61K47/48
The present invention enhanced antigen-directed to a use of the fusion protein as an immunogen enhancing agent (enhancer) for the specific T cell response. The fusion protein comprises the following: (a) the antigen-presenting cells (antigen-presenting cell; APC) - CD91 binding domain or the receptor-binding domain; (B) protein transduction (transduction) domain; And (c) antigens of pathogens (pathogen), which APC- binding domain or CD91 receptors in the N- terminus of the fusion protein-binding domain, and a protein antigen of the pathogen in transgenic C- terminal domain of the introduction. Wherein the protein transduction domain is selected from the group consisting of: (i) T cell sensitivity signal fusion polypeptide comprising the transduction peptide, the linker, and the translocation (translocation) peptides; (Ii) T cell-sensitivity signal-transduction peptides; And (iii) a translocation peptide of 34 to 112 amino acid residues in length.
公开/授权文献:
- KR101650364B1 항원-특이적인 T 세포 반응을 유도하는 면역 강화제로서 사용을 위한 융합 단백질 公开/授权日：2016-08-23